Bicara Therapeutics Inc. BCAX
$21.59
▲ +1.93% 24H
About
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors. Its primary program, ficerafusp alfa, is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees103
TickerBCAX
Statistics
Market Cap$1.41B
Revenue (TTM)$0
Net Income-$137.9M
Net Margin—
EPS$-2.52
P/E3.41
P/S—
P/B2.58
EV/EBITDA-4.67
ROE-32.3%
Dividend Yield—
Price$21.59
Data: Twelve Data · Revenue = mcap / P/S